FDA Moves to Real-Time Clinical Trial Patient Monitoring, Faster Drug Review

Summary: The FDA is changing how it tests new medicines so they can get to patients much faster. For 60 years, testing drugs meant a lot of waiting around. Scientists would finish a test, write a massive report, and then wait months for the FDA to read it. Now, the FDA is using artificial intelligence (AI) to look at patient data in real-time.

This means they can see if a new medicine is safe or working right away, without the long pauses! Companies like AstraZeneca and Amgen are already using this live-stream technology for new cancer treatments. By cutting out the waiting time, the FDA hopes to approve life-saving drugs much faster.

For more details, see rssapp-neurologyadvisor-com at neurologyadvisor.com/news/fda-moves-to-real-time-clinical-trial-patient-monitoring-faster-drug-review/ (opens in new tab)